Medibact GuidesShop at Medibact

Stacking Module

Melanotan I Stacking Module

Melanotan I (afamelanotide) is the selective counterpart to Melanotan II, and unlike its better-known sibling it has a genuine approved form — Scenesse, for erythropoietic protoporphyria. That approval is narrow, but it makes Melanotan I the better-characterised of the two.

Melanotan I Guide at MedibactMelanotan I calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Melanotan I

  • Melanotan I is a selective MC1R agonist. Its selectivity is the practical difference from Melanotan II, which is non-selective and therefore produces effects beyond pigmentation.
  • An approved form exists (afamelanotide, as Scenesse) for a rare photosensitivity disorder, delivered as an implant. That approval does not extend to research-market use for tanning.
  • It shares MC1R activity with Melanotan II and melanocortin activity with PT-141 — combining any of them is a class collision.
  • No controlled trial has studied it combined with anything.

Combinations in detail

Melanocortin pairing

Melanotan 1 + PT-141
Why it is proposed
Reported as separating pigmentation from sexual function using the selective agonist.
What is reported in practice
Separate subcutaneous compounds.
Cautions specific to this combination
Still a melanocortin class collision, and PT-141's documented blood-pressure effects apply. Selectivity narrows the overlap but does not remove it.

Skin-support pairing

Melanotan 1 + GHK-Cu
Why it is proposed
Pigmentation alongside copper-driven matrix remodeling — unrelated mechanisms in the same domain.
What is reported in practice
Separate compounds; GHK-Cu's strongest evidence is topical.
Cautions specific to this combination
Copper accumulation is GHK-Cu's constraint. Neither compound removes the need for dermatological awareness with any pigmentation agent.

Repair-focused pairing

Melanotan 1 + BPC-157
Why it is proposed
Pigmentation use alongside tissue repair; unrelated mechanisms.
What is reported in practice
Separate vials and schedules.
Cautions specific to this combination
No combination data.

What to avoid, and why

  • Combining with Melanotan II or PT-141 — overlapping melanocortin activity.
  • Reading the Scenesse approval as support for tanning use; the approved indication is a rare photosensitivity disorder and the delivery form is an implant.
  • Skipping dermatological awareness because Melanotan I is selective; pigmentation agents warrant skin monitoring regardless.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.